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The diagnosis and management of patients with renovascular disease and hypertension continue to elude healthcare providers. The advent of
novel imaging and interventional techniques, and increased understanding of the pathways leading to irreversible renal injury and renovas-
cular hypertension, have ushered in commendable attempts to optimize and finetune strategies to preserve or restore renal function and
control blood pressure. Large randomized clinical trials that compare different forms of therapy, and smaller trials that test novel experimen-
tal treatments, will hopefully help formulate innovative concepts and tools to manage the patient population with atherosclerotic renovas-
cular disease.
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Introduction
Major improvements in imaging, medical therapy, and techniques of
renal revascularization have changed the landscape of renovascular
disease during the past decade. This has been particularly true for
renal artery stenosis (RAS) secondary to atherosclerosis, which
remains one of the most common conditions that accelerate
hypertension and might be incidentally detected. Despite, or
perhaps because of, these developments, few clinical questions
provoke more controversy and debate than the optimal manage-
ment of patients with main RAS.
Prevalence
Recent studies have detected significant atherosclerotic RAS
(ARAS), defined as a decrease of at least 60% in luminal diameter,
in over 6% of persons aged over 65 years.1 Its prevalence increases
with age and in patients with known cardiovascular risk factors or
atherosclerosis, and ranges from 30% among patients with coron-
ary artery disease to 50% among elderly or those with diffuse
atherosclerotic vascular diseases. Buller et al.2 found RAS in 39%
of 851 patients undergoing cardiac catheterization with resistant
hypertension, renal impairment, flash pulmonary oedema, and/or
atherosclerosis in other vascular territories, with ARAS ≥ 50 in
14.3 and ≥70 in 7.3% of patients. In the USA, 12–14% of new
patients entering dialysis programs have ARAS, although its contri-
bution to end-stage renal disease is unclear.3
Rationale for treatment
Stenosis of the renal artery (STAR) leads to hypertension and
potentially to chronic renal failure. Despite successful reduction
in deaths from cardiovascular disease, chronic kidney disease con-
tinues to increase, and the incidence of ARAS as underlying cause
increases faster than any other cause.4 Even when silent,5 ARAS
constitutes an independent risk factor for aggravation of cardiovas-
cular disease,6,7 which in turn is the leading cause for a rate of
death of about 16%/year associated with ARAS. Increased risk of
cardiovascular disease in ARAS patients may result from activation
of the renin–angiotensin–aldosterone system (RAAS) and sym-
pathetic nervous systems, decreased glomerular filtration rate
(GFR), or concomitant atherosclerosis in other vascular beds.8
Damage to intra-renal structures is a foremost contributor to
renal impairment in ARAS patients, and the severity of histopatholo-
gical damage is an important determinant and predictor of renal func-
tional outcome.9 Renovascular hypertension secondary to ARAS
leads to higher rates of target organ injury compared with similar
levels of essential hypertension10 and to a greater decrease in
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renal function.11 Therefore, there is a clear healthcare need to
prevent deterioration of kidney function in the population. Indeed,
an American Heart Association (AHA) Science Advisory12 asserts
that the poor prognosis associated with ARAS requires increased
awareness of the disease and a need for early diagnosis, although
to date no study has shown a benefit to early treatment for ARAS.
Aetiology and characteristics
The two most common primary diseases of the renal arteries are
ARAS and fibromuscular dysplasia (FMD). Atherosclerosis
accounts for 90% of cases (Table 1) and usually involves the
ostium and proximal third of the main renal artery and the perire-
nal aorta. Data on progression of ARAS are inconsistent, with pro-
gressive stenosis reported in 51% 5 years after diagnosis and annual
occlusion rate of 5%/year in the 1990s.13,14 In the Dutch Renal
Artery Stenosis Intervention Cooperative (DRASTIC) study, 8/50
lesions (16%) in the drug cohort progressed to occlusion within
1 year.15 In contrast, in 1189 patients undergoing cardiac catheter-
ization, disease progression occurred in 133 (11.1%) patients, but
only 4 (0.3%) progressed to total occlusion.16 In 119 elderly par-
ticipants in the Cardiovascular Health Study, ARAS progressed at
1.3%/year at 8-year follow-up, but none occluded.17
Increased awareness for blood pressure control and number of
patients taking statins might decrease the rate of progression
nowadays.
Fibromuscular dysplasia is a heterogeneous group of idiopathic,
segmental, non-atherosclerotic vascular diseases that affect the
intima, media, and adventitia. Such lesions can be incidentally
detectable in 5% of normotensive and 16% of resistant hyperten-
sive individuals.18 When haemodynamically significant, FMD most
commonly affects women 15–50 years of age with normal
kidney function.19 Medial fibroplasia, characterized by its classic
‘string of beads’ appearance, represents the most common dysplas-
tic lesion. The natural history of renal FMD is poorly defined. Pro-
gression was described in over 35% of patients, but larger size
follow-up series are missing.
Rare aetiologies associated with the occurrence of RAS are large
artery vasculitides, antiphospholipid syndrome, and mid-aortic syn-
drome. Takayasu’s arteritis mainly affects the aorta and its major
branches, and RAS is present in 26%.20 Antiphospholipid
antibodies affect all vascular districts, and 26% of patients with
uncontrolled hypertension have RAS.21 Mid-aortic syndrome, a
rare congenital disease of the aorta and its branches, is associated
with . 60% chance of RAS.
Diagnosis
Anatomic and haemodynamic
Major advances in vascular imaging allow easier non-invasive
identification of vascular lesions than ever before. The threshold
for performing imaging procedures depends primarily on the
importance of excluding high-grade stenosis before proceeding
to long-term medical therapy, and on the commitment to
proceed with revascularization if needed. Magnetic resonance
(MR) and computed tomography (CT) angiography provide
detailed images of the aorta and renal arteries, often allowing
identification of multiple vessels, estimation of renal size, and
anatomy. The main limitation of all forms of angiography is
lack of information on renal flow or pressure distal to RAS;
e.g. a morphologically severe stenosis might not induce a
pressure gradient if flow is slow due to renal parenchymal
impairment. Doppler ultrasound (DUS) is operator-dependent
but highly specific in competent laboratories, and while it pro-
vides minimal information about kidney function, it can provide
reliable haemodynamic assessment of arterial lesions and identify
structural abnormalities in the kidney size.
Definition of a functionally significant RAS that justifies revascu-
larization remains unsettled. To cause hypertension, RAS should
produce a severe enough pressure gradient between the aorta
and afferent arterioles to upregulate renin production; a peak sys-
tolic pressure gradient .20 mmHg has been proposed.22 The gra-
dient is commonly measured simultaneously in the aorta and by a
4-F catheter distal to the lesion.23 Because the catheter might
obstruct flow, a more accurate, but costly alternative is a
0.014 in pressure wire. A 0.9 aorta to renal artery pressure gradi-
ent ratio corresponds to a systolic gradient ≈25 mmHg and
defines functionally significant RAS documented by renin release
in humans.24
Conventional catheter angiography
Intra-arterial digital subtraction angiography aims to confirm the
diagnosis of RAS, evaluate the extent of intra-renal vascular
disease, and identify associated aneurysmal or occlusive aortic
disease. It offers the highest spatial and temporal resolution for
anatomically visualizing main and branch arterial disease. A major
advantage of invasive imaging is that haemodynamic significance
can be directly measured and treated immediately. Guidelines for
renal artery revascularization suggested that a significant ARAS is
defined as a ≥ 50% diameter stenosis by visual estimation, associ-
ated with a peak translesional gradient ≥20 mmHg, or a mean gra-
dient ≥ 10 mmHg.22 Being invasive, however, conventional
catheter angiography (CCA) has the highest risk including ionizing
radiation and complications related to iodinated contrast and inter-
vention. Conventional catheter angiography is also the most
expensive in terms of financial cost and time, effort, and inconve-
nience for the patient.25
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Table 1 Aetiology of renal artery stenosis and
occlusion
Disease Prevalence
Atherosclerotic renal artery disease 85–90%
Fibromuscular disease 10%
Acute renal artery occlusion (thrombosis, embolism,
trauma)
,2%
Aortic dissection with renal artery involvement ,1%
Takayasu/giant cell arteritis ,1%
Mid-aortic syndrome Rare
Antiphospholipid syndrome Rare
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Recently, an AHA Science Advisory advocated screening CCA
as part of cardiac catheterization on patients at high risk for
ARAS who are potential candidates for revascularization.12
Although non-selective ‘drive-by angiography’ is relatively safe
and convenient, its usefulness remains questionable. Once diag-
nosed, many patients undergo revascularization, although it
remains difficult to predict who would benefit from intervention.26
Discordance between high technical success of percutaneous
transluminal renal angioplasty (PTRA) with or without stenting in
patients with ARAS and moderate clinical response rates is
partly explained by the limitations of angiography for the assess-
ment of haemodynamic and functional significance of RAS. Using
current criteria, a diameter stenosis . 50% by renal angiography
falsely identifies RAS as significant in 38% of cases compared
with trans-stenotic pressure gradient measurements, where
haemodynamic significance is defined as distal renal to aortic
pressure ratio ,0.9 (Table 2).24
Computed tomography
Advances in CT technology allow spiral multi-detector acquisitions
that provide accurate anatomic images of small renal arteries. The
median sensitivity and specificity of CT angiography (CTA) com-
pared with CCA are 94 and 93%, respectively,25 but it is less inva-
sive, and offers faster acquisition, better soft tissue visualization,
and multiplanar renal artery imaging. Its accuracy is comparable
with MR angiography (MRA), but CTA has added risks of ionizing
radiation and nephrotoxicity from iodinated contrast agents. Fur-
thermore, severe renal artery calcification may obscure luminal
narrowing, and the technique does not provide physiologic assess-
ment of the stenosis.
Magnetic resonance imaging
Compared with CCA, MRA has median sensitivity and specificity of
92 and 93.5% without and 96 and 93% with gadolinium,25 respect-
ively. It provides high-quality noninvasive anatomic images of the
renal arteries, and has become a common screening procedure
(Figure 1). The variety of available pulse sequences offer compre-
hensive evaluation of the kidneys without markedly increasing
scanning time or cost, but MRA is limited by frequent overestima-
tion of the degree of stenosis, especially with less-advanced
machines. A recent concern regarding the use of
gadolinium-enhanced MRI is nephrogenic systemic fibrosis, with
incidence of 1–6% for dialysis patients, and GFR , 30 mL/min
was designated as a relative contraindication.
Duplex ultrasound
Doppler ultrasound is an ideal screening modality for ARAS, as it is
noninvasive, radiation-free, low cost, and involves no contraindica-
tions due to renal failure or contrast allergy. It can be applied seri-
ally to monitor disease progression and allows direct measurement
of physiologic patterns, like flow velocities and vascular resistance.
However, commonly used criteria describing a stenosis. 60%
may falsely identify significant RAS compared with trans-stenotic
pressure gradients (Table 2).24
The major drawbacks of DUS are operator-dependence and
lack of uniformity in diagnosis. Common pitfalls are failure to visu-
alize the entire renal artery, accessory renal arteries, and missing
the highest peak systolic velocity during spectral Doppler tracing.27
Peak systolic velocity . 200–320 cm/s22,24 in the main renal
artery associated with post-stenotic turbulence is most frequently
used to determine relevant RAS and correlates with ≥60% angio-
graphic RAS (Figure 1) with sensitivity and specificity of 71–98 and
62–98%, respectively. Another approach is to image the
intra-renal interlobar or segmental arteries. A side to side differ-
ence of .0.05 of the resistive index is the most frequently used
indirect duplex parameter (Figure 2), with specificity of 99% for
the detection of at least 70% RAS and a sensitivity of 77%.28
Other indirect parameters include missing early systolic peak,
retarded acceleration, and increased acceleration time, which are
less specific and ideally should be used to support the diagnosis
based on peak systolic velocity.29
Radermacher et al.30 reported that the resistance index by DUS
provides a measure of parenchymal disease that can predict
improved kidney function or blood pressure control after stenting,
but others could not replicate these findings.31
Functional
Activation of the renin–angiotensin system
The link between activation of the RAAS and hypertension has
evoked development of agents capable of blocking this system,
such as angiotensin receptor blockers (ARB) or converting
enzyme (ACE) inhibitors. Systemic RAAS activation appears to
be transient in untreated individuals, and blood pressure sub-
sequently sustained by alternative pressor pathways, such as oxi-
dative stress and endothelial dysfunction.32 Renin release results
from a decline of kidney perfusion pressure associated with a
trans-lesion gradient of 10–20%,23 in turn resulting from a 70–
80% decrease in luminal cross-sectional area.33,34 Lateralization
of plasma renin activity to the stenotic kidney suggests a haemody-
namically significant stenosis.
Methods of measuring the RAAS response include renin sodium
profiling, assessment of plasma renin activity before and after cap-
topril, effect of ACE-inhibitors on blood pressure and renal
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Table 2 Diagnostic performance of quantitative
angiography and Doppler-derived parameters for
identifying significant RAS (distal renal to aortic















Renal aortic ratio 3.80 2.98–4.10
Optimal cut-off values and 95% confidence intervals (bootstrap procedure).
I. Baumgartner and L.O. Lerman1592
function, and captopril renography for differential renal perfusion.
Captopril renography has lost popularity, as it has little predictive
value and provides no direct visualization the renal vessels.
However, it can assess the relative function of the kidneys in the
presence of a unilateral high-grade stenosis.34
These RAAS tests are not recommended in most elderly
patients with ARAS, in whom hypertension is often not renin-
dependent and imaging techniques are preferable, but are more
useful for identifying patients with FMD.
Tomographic imaging
Tomographic imaging techniques (MR, CT, and positron emission
tomography) have several potential advantages for the assessment
of ARAS beyond visualization of the renal artery. First, their cross-
sectional capability allows assessment of both kidneys individually
and simultaneously. Second, they can provide same session quan-
titative assessments of the haemodynamics and function of the
post-stenotic kidney.
Both CT and MR have been validated for the assessments of
renal blood flow and GFR. Computed tomography was used to
assess renal functional reserve, tubular function, and endothelial
function.35,36 Positron emission tomography can quantify renal cor-
tical perfusion37 and metabolic activity; further studies are needed
to realize its full potential.
An emerging MR technique to investigate the functional effects
of ARAS on the kidney, Blood Oxygen Level Dependent
(BOLD) MRI, assesses renal levels of deoxyhaemoglobin, and
thereby indirectly renal oxygen content. Textor et al.38 have
shown that furosemide, which inhibits medullary tubular transport
and oxygen consumption, decreases medullary deoxyhaemoglobin
Figure 1 Flow chart of primary renal artery assessment using duplex sonography (A) or magnetic resonance (MR) angiography (B). RAS, renal
artery stenosis; PSV, peak systolic velocity; ESP, early systolic peak; RAR, renal aortic ratio; RI, resistance index; RI difference, side to side;
PTRA(S), percutaneous transluminal renal angioplasty (with stenting).
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in normal nephrogram human kidneys, while atrophic kidneys distal
to total occlusion did not respond (Figure 3), suggesting low viabi-
lity. This technique offers much promise, as it involves no radiation
or contrast agents.
The sophistication and wealth of information that tomographic
imaging tools provide also underlie their high cost and limited avail-
ability, and their use is currently mostly experimental and confined
to large medical centres.
Treatment
Various treatment regimens are effective for lowering blood
pressure in ARAS patients, although kidney function may worsen
over time.39 Antihypertensive therapy was found to be effective
at reducing blood pressure, but data on clinical outcome event
rates were sparse or inconsistent across studies.40,41
Medical
Most patients with haemodynamically significant ARAS tolerate
RAAS blockade without difficulty. However, ACE-inhibitors or
ARB can reduce glomerular capillary hydrostatic pressure
enough to cause a transient decrease in GFR and raise serum crea-
tinine, warranting caution and close follow-up. Acute deterioration
in renal function secondary to RAAS blockade might be observed
mainly during renovascular obstruction of the entire renal mass,
particularly in the presence of severe congestive heart failure,
use of high-dose loop diuretics, volume contraction, and
poor baseline renal function.42 A significant (≥30%) fall in GFR
(or .0.5 mg/dL rise in creatinine) may be an indication to consider
renal revascularization.
Because ARAS is frequently accompanied by cardiovascular risk
factors, it is imperative to manage them aggressively. Lowering lipid
levels, smoking cessation, and maintaining acceptable glucose levels
all require consideration.
Importantly, experimental and clinical evidence shows that
damage to the kidney tissue and microcirculation by mechanisms,
such as oxidative stress, microvascular loss, or enhance fibrogenic
cascades, is a major determinant of renal outcomes, supporting the
notion that interventions targeting renal injury pathways might
constitute an adjunct or even alternative strategy to ensure ade-
quate recovery. Interestingly, recent experimental studies have
suggested that novel experimental approaches to treat the renal
parenchyma directly, such as antioxidants,36 statins,43 and endo-
thelial progenitor cells35,44 (Figure 4), may decrease renal injury
even without correcting the obstructive RAS lesion. Hence, revas-
cularization of the stenotic renal artery may be less crucial that
previously thought. Moreover, a recent pilot study showed that
adding to the standard antihypertensive treatment after revascular-
ization nebivolol, a new generation beta-blocker that releases nitric
oxide, improved GFR, and proteinuria.45
Revascularization
Overall, both invasive and medical therapy may decrease blood
pressure, but evidence weakly supports a conclusion that revascu-
larization may result in better blood pressure control, particularly
in subjects with bilateral disease. Evidence supporting benefit of
aggressive diagnosis and timing of renal revascularization remains
unclear. Patients treated with medical therapy alone risk deterio-
ration of kidney function with worsening morbidity and mortality.
Revascularization can provide immediate improvement in kidney
function and blood pressure in selected patients, but carries a
Figure 2 Relevant indirect Doppler criteria to diagnose renal artery stenosis (RAS). (Left) Intra-parenchymal colour Doppler spectrum. (Top
right) Normal right intra-parenchymal Doppler spectrum. The early systolic peak (arrow) and normal acceleration time (time span between
end-diastolic and systolic peak) indicate normal renal blood flow. Normal resistance index (RI; ratio of end-diastolic and systolic peak velocities)
argues against parenchymal disease compromising blood flow. (Bottom right) Left-sided intra-parenchymal Doppler spectrum lacking early sys-
tolic peak, with increased acceleration time and a flattened Doppler spectrum. Side to side difference of the intrarenal RI . 0.05 indicates hae-
modynamically significant (.70%) RAS.
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small risk for mortality or substantial morbidity.46 In practice, costs
and risks of both endovascular and surgical procedures limit their
universal application, especially for renovascular lesions that pose
no immediate hazard or risk of progression. A hyperaemic systolic
gradient ≥21 mmHg seems to be the strongest predictor of hyper-
tension improvement after stenting in hypertensive patients with
unilateral RAS,27,47 while diameter stenosis . 50% by angiography
and renal fractional flow reserve are not.
There is general consensus, but no robust evidence, that renal
revascularization should be indicated in patients with anatomically
significant RAS who present with clinical scenarios like sudden
onset, ‘flash’ pulmonary oedema unrelated to acute coronary syn-
drome, congestive heart failure with preserved left ventricular
function, and acute oligoanuric renal failure with global kidney
ischaemia. Others feel that ARAS patients with multi-drug-resistant
renovascular hypertension, advanced CKD (stages 4–5),48 or stea-
dily deteriorating renal function should undergo revascularization
(Table 3, Figure 5). However, there is incomplete evidence to
support its use in these situations, which is also true for the vast
majority of ARAS patients who present with asymptomatic
chronic kidney disease or hypertension and severe RAS.
Interventional
Interventional treatment involves conventional PTRA without or
with stenting. Guiding catheter techniques are commonly
employed, which involve the use of coronary or peripheral guide
wires, balloon catheters, and pre-mounted stents. Treatment
with aspirin before the procedure, and using low osmolar contrast
media and heparin during the procedure, are recommended.19
Dual 28-day antiplatelet therapy is standard of care in most insti-
tutions, translated from coronary interventions.
Conventional PTRA is considered the treatment of choice for
patients with uncontrolled hypertension and FMD. The procedure
is successful in 82–100% of patients, and stenosis recurs in
Figure 3 Magnetic resonance angiogram in a patient with bilateral RAS (A), more severe on the left. BOLD-MRI demonstrated low signal both
before and after furosemide (B). The normal size right kidney had higher baseline signal that fell in response to furosemide, suggesting sustained
oxygen consumption and tubular function. From ref.38, with permission.
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10–11%.49,50 It is less effective for ARAS, because of the potential
for dissection and elastic recoil in ostial lesions, with restenosis
incidence of 10–47%.51 Introduction of stents has extended the
efficacy of endovascular techniques to technical success of 94–
100%, residual diameter stenoses ,10%, and restenosis rates of
11–23% at 1 year.52 The timing of revascularization remains con-
troversial. With poor evidence from randomized trials, some do
not advocate its use unless there is bilateral RAS and creatinine
elevation, but preceding serum creatinine concentration elevation
might be a better approach.19 The risk of death rises two—three-
fold for each 88 mmol/L increment in the baseline creatinine level,
a major determinant of postoperative renal failure.53 Baseline crea-
tinine concentration .130 mmol/L is the strongest independent
predictor of death within 4 years after renal stenting.54
Comparison of angioplasty with medical treatment of atherosclerotic
renal artery stenosis
Two randomized controlled trials (RCT, level II evidence) compared
PTRA to medical treatment with ≥ 6 months of follow-up,15,55 but
were underpowered for clinical outcomes including mortality, cardi-
ovascular, and kidney events. Stents were used rarely and medical
therapies varied both between and within studies. The EMMA trial
investigators concluded that PTRA in unilateral ARAS has some
drug sparing potential, but that its potential for lowering blood
pressure was overestimated.15,55 DRASTIC showed no significant
differences between the angioplasty and drug therapy. Twenty-one
cohort studies (uncontrolled, level IV evidence) of PTRAplus stenting
(PTRAS) published before 2007 showednounifying pattern regarding
mortality rates. Several found that patients remained at increased risk
of cardiovascular disease after PTRAS.49 In contrast to medically
treated patients, some patients showed improved kidney function.
Cure, improvement, or worsening of arterial hypertension ranged
4–18, 35–79, and 0–13%, respectively. Some studies reported
reduction in the New York Heart Association Functional Class after
stent placement in patients with either bilateral disease or stenosis
to a solitary functioning kidney.56 Individual patient categories,
such as those with congestive heart failure and pulmonary
oedema, showed benefit from renal revascularization.50 An
updated comparative effectiveness analysis of studies was published
in 2007.46
Figure 4 Representative micro-CT images of the swine kidney microcirculation (A) and fibrosis (B, trichrome staining, ×20) in normal, ather-
osclerotic RAS (ARAS), and ARAS pigs treated with intrarenal endothelial progenitor cells (EPC) 4 weeks earlier. EPC delivery increased micro-
vascular density in the stenotic kidney without the need for revascularization. From ref.35, with permission.
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Table 3 Indications for renal revascularization
Resistant hypertension
Failure of medical therapy despite full dose of ≥3 drugs, including
diuretics




Recent rise in serum creatinine
Loss of GFR during antihypertensive therapy, e.g. ACE-inhibition/
ARB
Circulatory congestion, recurrent ‘flash’ pulmonary oedema unrelated
to acute coronary syndrome
Refractory congestive heart failure with bilateral renal artery stenosis
GFR, glomerular filtration rate; ACE, angiotensin converting enzyme; ARB,
angiotensin receptor blockade (adapted from ref.67).
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Major randomized controlled trials
The angioplasty and stenting for renal artery lesions (ASTRAL) trial
is so far the largest published RCT to compare PTRAS combined
with medical therapy to medical therapy alone for improvement in
renal function.57 In 806 patients with ARAS, differences in renal
function, blood pressure, kidney, and cardiovascular events, and
mortality were all unimpressive. The decline in renal function
over time was slightly slower in the revascularization group, but
not statistically significantly. The medical management group
required a slightly higher number of antihypertensive drugs, reach-
ing statistical, but not clinical significance.
There are several caveats associated with the ASTRAL trial, the
most significant among which is selection bias. Patients were
enrolled if they had substantial anatomical atherosclerotic stenosis
in at least one renal artery that was considered potentially suitable
for endovascular revascularization, and if the patient’s doctor was
uncertain that the patient would definitely have a worthwhile clini-
cal benefit from revascularization. Both the method of revascular-
ization and medical therapy regimen were left to local investigators
and consequently were varied and poorly defined. Moreover,
despite poor reliability of visual estimation of stenosis severity,
there was no central core laboratory to review angiographic
studies.
The stent placement and blood pressure and lipid lowering for
the prevention of progression of renal dysfunction caused by
atherosclerotic ostial STAR study is a European multicentre trial,
aimed to detect a ≥20% decrease in creatinine clearance. At 2
years, the primary endpoint had been reached in 16% of the
patients in the stent group and 22% in the medication group, a
non-statistically significant and inconclusive difference, given the
wide confidence intervals. No difference was observed in second-
ary endpoints (blood pressure control, cardiovascular morbidity,
and death).58 This largely underpowered trial showed that renal
function deterioration might progress despite successful revascu-
larization, underscoring the complex cause of ischaemic nephropa-
thy with an important parenchymal component affected by
atherosclerosis risk factors. However, STAR enrolled a third of
patients with RAS ,70%, and a quarter did not receive the
assigned treatment but were analysed as treated due to the inten-
tion to treat study design. Moreover, it showed that if technical skill
is insufficient, a considerable number of stent-related compli-
cations can occur and may cause more harm than benefit in a com-
munity setting. Whether revascularization is indicated in patients
presenting with acute renal injury, severe RAS and sudden onset
pulmonary oedema unrelated to acute coronary syndrome,
rapidly deteriorating renal function, renal function deterioration
with the RAAS blockade, or unilateral RAS and contralateral occlu-
sion of the renal artery,59 was answered by neither trial.
The vascular community now awaits results from the Cardiovas-
cular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial,
which tests the hypothesis that stenting ARAS .60% (pressure
gradient. 20 mmHg) in patients with systolic hypertension
reduces the incidence of cardiovascular and renal events.60 To
date, no major differences in patient survival were evident
between patients subjected to surgical vs. endovascular pro-
cedures, although few randomized trials have addressed this
issue directly. Resolution of this issue with current patient demo-
graphics and optimized medical therapy is a major objective of
the CORAL study. Unlike ASTRAL and STAR, CORAL is studying
patients with difficult to control hypertension and systolic blood
pressure ≥155 mmHg on two or more drugs. Chronic kidney
disease is not an exclusion criterion unless serum creatinine con-
centration is. 3.0 mg/dL.
RADAR is another ongoing, prospective, multi-centre trial to
evaluate the clinical impact of PTRAS on impaired renal function
in patients with ≥70% ARAS.61 Three hundred patients will be
Figure 5 Relationship between changes in slope values of reciprocal serum creatinine plot vs. time before (1 year) and after (3 months)
percutaneous renal artery (RA) angioplasty with (PTRAS) or without stenting. Three patients who died within 30 days after PTRAS were
excluded. Adapted from ref.68
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randomized to best medical treatment vs. best medical treatment
plus PTRAS. Hopefully, CORAL and RADAR will help answer
remaining questions. Indeed, unless the CORAL trial reveals
clear benefit of intervention, the future of PTRAS is in doubt,
although most clinicians believe a subgroup of patients do
benefit from revascularization.
Drug-eluting stents and distal embolic protection devices
Currently, the only completed study on drug-eluting stents (DES)
in ostial ARAS is the GREAT trial,62 which compared sirolimus DES
to bare metal stents in 102 patients. Relative risk reduction in
angiographic binary renal artery in-stent restenosis was 50%,
which was statistically insignificant (7 vs. 14%, P ¼ ns), because
the study was underpowered. In-stent stenosis, binary restenosis
rates, late lumen loss, and repeat revascularization were all lower
in the DES group. At present, DES are manufactured solely for
use in coronary vessels, and the sirolimus DES is not commercially
available. Given the lack of outcome data, considerable expenses,
and cost associated with post-procedure need for long-term anti-
platelet therapy with aspirin and clopidogrel, widespread use of
DES is not recommended.
The contribution of distal embolization to worsening renal func-
tion after stenting has grown interest in using embolic protection
devices (EPD). RESIST, a randomized phase II trial in 100 patients
plus a glycoprotein IIb/IIIa inhibitor in a 2 × 2 factorial design,63
demonstrated no overall improvement in GFR with the use of a
filter-based EPD, perhaps because of increased platelet aggregation
or escaped renal atheroemboli associated with the device. The rate
of platelet-rich emboli was 50% with neither abciximab nor a thie-
nopyridine, 36% with thienopyridine only, 15% abciximab only, and
0% in patients who received both. The aim of the study, small
sample size, and non-randomization of thienopyridine use limit
more general conclusions regarding antplatelet therapy.64
Surgical revascularization
Renal artery surgery offers major benefits for patients undergoing
surgical repair of the aorta or nephrectomy, and for patients
with complex disease of the renal arteries, e.g. aneurysms or
failed endovascular procedures. Surgical procedures may include
renal artery bypass grafting, endarterectomy, or occasionally
extra anatomic repair using anastomosis to the hepatic or splenic
arteries. Thirty-day mortality rates range between 3.7 and 9.4%46
and is increased by the need for aortic reconstruction or bilateral
renal bypass, severe preoperative azotemia, and the use of an
aortic graft for aortorenal bypass. Early graft failure that occurs
in 1.4–10%65 is the strongest independent predictor of periopera-
tive death. The major arguments against surgical revascularization
include a higher mortality linked to surgery in patients with
co-morbidities and the similar outcome benefits of endovascular
repair.
Revascularization in fibromuscular dysplasia
Fibromuscular dysplasia predominantly affects young women with
normal kidney function, so that renal artery revascularization is
expected to be relatively successful. No RCTs or comprehensive
systematic reviews assessed blood pressure outcomes in patients
with FMD. However, a recent meta analysis on the effect of
revascularization in patients with FMD included 50 studies con-
cerning PTRA and 25 concerning surgery.66 Hypertension was
cured after PTRA or surgery in 46 and 55% of patients, respect-
ively, with large variations across studies. The probability of cure
was negatively associated with age, hypertension duration, medial-
type FMD, time of publication, and more stringent definitions of
cure. Cure rates after PTRA or surgery based on current definition
(blood pressure ,140/90 mmHg without treatment) were only 36
and 54%, respectively. The risk of periprocedural complications
was substantial, and tended to be lower after PTRA, but selection
criteria may have differed between study populations. Advances in
vascular imaging and more liberal advice to undergo PTRA in
patients with renal FMD and hypertension may explain the disap-
pointing blood pressure control in more recent publications.
Conclusions
The indications for revascularization of the renal arteries are the
subject of continuing controversy. Based on the results of the
STAR and ASTRAL trials, the practice of indiscriminately revascu-
larizing ARAS is no longer tenable. The challenge is to identify
those selected patients who would respond, and to intervene
early enough to reverse kidney damage. Intervention is not rec-
ommended if renal function has remained stable over the past
6–12 months and if hypertension can be controlled with an accep-
table medical regimen. Anatomically relevant RAS .70% should
be verified by functional measurements as systolic pressure gradi-
ent ≥21 mmHg or Pd/Pa pressure ratio ,0.9. The best evidence
supporting intervention seems to be for bilateral stenosis with
‘flash’ pulmonary oedema unrelated to acute coronary syndrome,
but the evidence is from retrospective studies. Indeed, in patients
with ARAS, control of hypertension may be facilitated by revascu-
larization, but cure of hypertension is unusual, and preservation of
renal function may be a more realistic goal. The choice of revascu-
larization technique depends on the presence of associated aortoi-
liac diseases. For complicated cases, surgical revascularization and
renal bypass are both acceptable. Novel approaches to attenuate
kidney tissue injury and increase its viability regardless of revascu-
larization may prove vital and are under investigation.
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